source
- AbiVax falls as safety worries cloud ‘landmark’ immune drug resultsA handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.BioPharma Dive · 1mo ago↗ source
- How one state’s medical meal program lowered health care costsMedicaid work requirements, fast-tracked funding for experimental Ebola vaccines, and more health news from Morning RoundsSTAT · 1mo ago↗ source
- ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancerAt the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.BioPharma Dive · 1mo ago